The Winckelmann300 Project: Dissemination of Culture with Virtual Reality at the Capitoline Museum in Rome

The best way to disseminate culture is, nowadays, the creation of scenarios with virtual and augmented reality that supply the visitors of museums with a powerful, interactive tool that allows to learn sometimes difficult concepts in an easy, entertaining way. 3D models derived from reality-based techniques are nowadays used to preserve, document and restore historical artefacts. These digital contents are also powerful instrument to interactively communicate their significance to non-specialist, making easier to understand concepts sometimes complicated or not clear. Virtual and Augmented Reality are surely a valid tool to interact with 3D models and a fundamental help in making culture more accessible to the wide public. These technologies can help the museum curators to adapt the cultural proposal and the information about the artefacts based on the different type of visitor’s categories. These technologies allow visitors to travel through space and time and have a great educative function permitting to explain in an easy and attractive way information and concepts that could prove to be complicated. The aim of this paper is to create a virtual scenario and an augmented reality app to recreate specific spaces in the Capitoline Museum in Rome as they were during Winckelmann’s time, placing specific statues in their original position in the 18th century

Apparatus for synthesizing and separating synthesis products e.g. gaseous and liquid phases on bed, maintains heavier liquid phase at lower portion of first meatus due to gravity and lighter liquid phase at upper portion of meatus

NOVELTY - The apparatus has header that is set to make the heavier and lighter liquid phases flow along outer side surface of a third tube (8) as far as first closure element (13). The third tube is provided with second side openings for directly connecting the first and second meatus. The heavier liquid phase is maintained at lower portion of the first meatus due to gravity and lighter liquid phase is maintained at upper portion of the first meatus until the liquid phases fall into a fourth tube (9). The heavier liquid phase is collectible through a collection hole (12). USE - Apparatus e.g. reactor/separator for synthesizing and separating synthesis products e.g. gaseous phase and heavier and lighter liquid phases on catalytic bed, used in production of biodiesel. ADVANTAGE - Since heavier liquid phase is maintained at lower portion of the first meatus due to gravity and lighter liquid phase is maintained at upper portion of the first meatus, sedimentation separation of the liquid phases is improved. The structure of the apparatus is simplified and the apparatus is constructed easily. The efficacy and use of catalyst are maximized. DETAILED DESCRIPTION - The apparatus has synthesis module (M1) that is set with a first tube (1) which is provided with an opening at one end and closed at second end by a mesh (7). The first tube is adapted to contain a catalytic bed (6). A separation module (M2) is set to separate heavier and lighter liquid phases and gaseous phase originating from the synthesis module. A second tube (1') is arranged adjacent to second end of the first tube. A first closure element is provided with a through hole for sole passage of the second liquid and of the gaseous phase. A third tube is affixed to first end of second tube. A first meatus is set between second tube and the third tube. The fourth tube is set inside the third tube so as to define a second meatus between the third tube and the fourth tube. A separation zone is set between the heavier and lighter liquid phases. A collection hole is set in the second tube to collect the heavier liquid phase. The third tube is set with first side openings at first end, and is set with a header for collecting the liquid phases originating from the synthesis module. The first meatus is directly inserted into the third tube and subsequently into the fourth tube. A control system is set between the liquid phases, to check and maintain interface level below the upper end of the first side openings. The control system has interface level indicator that is connected to the second tube by second side holes envisaged in side surface of the second tube. One of the second side holes is arranged in proximity of the first closure element and other is positioned above the upper end of the first side openings. The protrusions are arranged along cylindrical side surface of the third tube, and are separated by spaces for passage of the liquid phases from the header to the first meatus. A redistribution module (M3) is set to redistribute the lighter liquid phase and gaseous phase originating from the fourth tube. A fifth tube (1") is arranged adjacent to second end of the second tube. The closure element is set with a central perforated area. A sixth tube (14) is set to descent and release of the gaseous phase. The central perforated area is provided with several holes for homogeneous distribution of lighter liquid phase downstream of the redistribution module. The sixth tube is affixed to a second closure element (15). The mesh is provided with a passage area. The synthesis module, separation module and redistribution module are vertically-stacked. An INDEPENDENT CLAIM is included for a method for synthesizing and separating synthesis products e.g. gaseous phase and heavier and lighter liquid phases on catalytic bed, involves synthesizing on a catalytic bed and producing the synthesis products. The liquid phases and gaseous phase are separated in the separation module

Octreotide 24‐h prophylaxis in patients at high risk for post‐ERCP pancreatitis: results of a multicenter, randomized, controlled trial

Background:Pharmacological prophylaxis of post‐ERCP pancreatitis is costly and not useful in most non‐selected patients, in whom the incidence of pancreatitis is 5% or less. However, it could be useful and probably cost‐effective, in patients at high risk for this complication, where the post‐procedure pancreatitis rate is 10% and more.Aim:To assess the efficacy of octreotide in reducing the incidence and severity of post‐ERCP pancreatitis and procedure‐related hospital stay, in subjects with known patient‐related risk factors.Methods:A total of 120 patients were randomly allocated to receive octreotide or not, in a multicentre, randomized, controlled trial. The drug was given subcutaneously, 200 μg t.d.s., starting 24 h before the ERCP procedure, in patients with either sphincter of Oddi dysfunction, or a history of relapsing pancreatitis or post‐ERCP pancreatitis, or who were aged under 35 years, or who had a small common bile duct diameter (< 8 mm).Results:A total of 114 patients (58 in the octreotide group and 56 in the control group) completed the trial. Post‐procedure pancreatitis occurred in seven octreotide‐treated patients (12.0%) and eight controls (14.3%). The two groups showed no significant differences in the incidence or severity of pancreatitis. Twenty‐four hours after the procedure, severe hyperamylasemia (more than five times the upper normal limit) without pancreatic‐like pain was recorded in three octreotide‐treated patients (5.2%) and six controls (10.7%), the difference being not significant.Conclusion:Twenty‐four‐hour prophylaxis with octreotide proved ineffective in preventing post‐ERCP pancreatitis and in avoiding 24‐h severe hyperamylasemia in high‐risk patients

Investigating serum and tissue expression identified a cytokine/chemokine signature as a highly effective melanoma marker

The identification of reliable and quantitative melanoma biomarkers may help an early diagnosis and may directly affect melanoma mortality and morbidity. The aim of the present study was to identify effective biomarkers by investigating the expression of 27 cytokines/chemokines in melanoma compared to healthy controls, both in serum and in tissue samples. Serum samples were from 232 patients recruited at the IDI-IRCCS hospital. Expression was quantified by xMAP technology, on 27 cytokines/chemokines, compared to the control sera. RNA expression data of the same 27 molecules were obtained from 511 melanoma-and healthy-tissue samples, from the GENT2 database. Statistical analysis involved a 3-step approach: analysis of the single-molecules by Mann–Whitney analysis; analysis of paired-molecules by Pearson correlation; and profile analysis by the machine learning algorithm Support Vector Machine (SVM). Single-molecule analysis of serum expression identified IL-1b, IL-6, IP-10, PDGF-BB, and RANTES differently expressed in melanoma (p &lt; 0.05). Expression of IL-8, GM-CSF, MCP-1, and TNF-α was found to be significantly correlated with Breslow thickness. Eotaxin and MCP-1 were found differentially expressed in male vs. female patients. Tissue expression analysis identified very effective marker/predictor genes, namely, IL-1Ra, IL-7, MIP-1a, and MIP-1b, with individual AUC values of 0.88, 0.86, 0.93, 0.87, respectively. SVM analysis of the tissue expression data identified the combination of these four molecules as the most effective signature to discriminate melanoma patients (AUC = 0.98). Validation, using the GEPIA2 database on an additional 1019 independent samples, fully confirmed these observations. The present study demonstrates, for the first time, that the IL-1Ra, IL-7, MIP-1a, and MIP-1b gene signature discriminates melanoma from control tissues with extremely high efficacy. We therefore propose this 4-molecule combination as an effective melanoma marker

The CAST Time Projection Chamber

One of the three X-ray detectors of the CAST experiment searching for solar axions is a Time Projection Chamber (TPC) with a multi-wire proportional counter (MWPC) as a readout structure. Its design has been optimized to provide high sensitivity to the detection of the low intensity X-ray signal expected in the CAST experiment. A low hardware threshold of 0.8 keV is safely set during normal data taking periods, and the overall efficiency for the detection of photons coming from conversion of solar axions is 62 %. Shielding has been installed around the detector, lowering the background level to 4.10 x 10^-5 counts/cm^2/s/keV between 1 and 10 keV. During phase I of the CAST experiment the TPC has provided robust and stable operation, thus contributing with a competitive result to the overall CAST limit on axion-photon coupling and mass.Comment: 19 pages, 11 figures and images, submitted to New Journal of Physic

Search for solar axions using Li-7

We describe a novel approach to the search for solar, near-monochromatic hadronic axions, the latter being suggested to be created in the solar core during M1 transitions between the first excited level of Li-7, at 478 keV, and the ground state. As a result of Doppler broadening, in principle these axions can be detected via resonant absorption by the same nuclide on the Earth. Excited nuclei of Li-7 are produced in the solar interior by Be-7 electron capture and thus the axions are accompanied by emission of Be-7 solar neutrinos of energy 384 keV. An experiment was made which has yielded an upper limit on hadronic axion mass of 32 keV at the 95% confidence level.Comment: revtex, 4 pages with 2 figures, title revised, minor changes, matches version to appear in Phys. Rev.

Intracochlear schwannoma presenting as diffuse cochlear enhancement: diagnostic challenges of a rare cause of deafness

Intracochlear schwannoma is a rare, treatable, cause of unilateral hearing loss. Due to the small size, position, and variable clinical and imaging features, diagnosis presents a significant challenge and is often delayed. We present a case of a patient with an intracochlear schwannoma presenting as a diffuse enhancement of the cochlea, mimicking an infectious or inflammatory process. The absence of focal nodularity in this lesion on multiple high-resolution MRI examinations led to a delay of over 3 years from the patient’s initial presentation to surgical diagnosis. Clinical history and examination, imaging features, pathologic findings, and surgical management options are described